# US 2008/0306089 A1 · Prolinamide-tetrazole derivatives as nk3 receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306089 A1
- Document ID: US20080306089A1
- Status: Published application
- Kind: A1
- Application number: 12/129,720
- Filed: 2008-05-30
- Published: 2008-12-11
- Earliest claimed: 2007-06-07
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Bo Han; Henner Knust; Matthias Nettekoven; Hasane Ratni; Xihan Wu
- Web page: https://patentgrep.com/patent/US20080306089A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula I wherein R1, R2, R3, and n are as defined herein or to a pharmaceutically acceptable acid addition salt thereof. These compounds are NK3 receptor antagonists, useful for the treatment of such disorders as depression, pain, bipolar disorders, psychosis, Parkinson's disease, schizophrenia, anxiety, and attention deficit hyperactivity disorder (ADHD).

## Claims

### Claim 1

A compound of formula I
wherein
R1 is cycloalkyl or is phenyl unsubstituted or substituted by one or two halogen atoms;
R2 is hydrogen or halogen;
R3 is hydrogen, CN, lower alkoxy, lower alkyl or halogen; and
n is 0, 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1, wherein R1 is phenyl unsubstituted or substituted by one or two halogen atoms.

### Claim 3 (depends on 2)

A compound of claim 2, selected from the group consisting of
2-(4-{(2S,4S)-1-benzyl-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile,
2-{4-[(2S,4S)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-1-(2-fluoro-benzyl)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-1-(3-fluoro-benzyl)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-1-(4-fluoro-benzyl)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-(4-{(2S,4S)-1-(2-chloro-benzyl)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile,
2-(4-{(2S,4S)-1-(3-chloro-benzyl)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile,
2-(4-{(2S,4S)-1-(4-chloro-benzyl)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile and
2-(4-{(2S,4S)-1-(3,4-difluoro-benzyl)-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R1 is cycloalkyl.

### Claim 5 (depends on 4)

A compound of claim 4, wherein the compound is 2-(4-{(2S,4S)-1-cyclohexylmethyl-4-[5-(2,4-difluoro-phenyl)-tetrazol-2-yl]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile.

### Claim 6

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
R1 is cycloalkyl or is phenyl unsubstituted or substituted by one or two halogen atoms;
R2 is hydrogen or halogen;
R3 is hydrogen, CN, lower alkoxy, lower alkyl or halogen; and
n is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 7

A process for preparation of a compound of formula I,
wherein
R1 is cycloalkyl or is phenyl unsubstituted or substituted by one or two halogen atoms;
R2 is hydrogen or halogen;
R3 is hydrogen, CN, lower alkoxy, lower alkyl or halogen; and
n is 0, 1 or 2;
which process comprises
reacting a compound of formula
with R1C(O)H, acetic acid and NaBH(OAc)3
to give a compound of formula
